التداخل بين سيليجيلين وتولكابون

Baseline treatment with dopamine agonists or selegiline did not appear to increase the likelihood of experiencing orthostatic hypotension when treated with Tolcapone tablets.

Tolcapone can be taken concomitantly with a selective MAO-B inhibitor (e.g., selegiline).

In clinical trials, patients receiving Tolcapone tablets/levodopa preparations reported a similar adverse event profile independent of whether or not they were also concomitantly administered selegiline (a selective MAO-B inhibitor).

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism.

For this reason, patients should ordinarily not be treated concomitantly with Tolcapone tablets and a non-selective MAO inhibitor.